Clinical tool

QTc Calculator (Fridericia and Bazett) for Anticancer Drugs

Corrected QT, CTCAE grade and action with QT-prolonging drugs

Updated: 27 October 20261 min read3 references

QT corrected with the Fridericia formula (preferred in oncology) and Bazett.

This calculator needs JavaScript; the formula and its interpretation are in the text of this page.

An aid for clinicians; it does not replace clinical judgement, local protocols or the drug label. Double-check every result before prescribing.

Which formula?

Bazett over-corrects QT at high heart rates; Fridericia and Framingham were more accurate in comparisons [1]. Most anticancer drug labels and the ESC guideline use Fridericia for monitoring [3].

Examples of anticancer drugs with QT risk [2]
DrugNote
Arsenic trioxideECG and electrolyte monitoring before and during treatment
RibociclibECG at baseline, day 14 of cycle 1 and start of cycle 2
Nilotinib, vandetanibECG monitoring; avoid other QT-prolonging drugs
High-dose IV ondansetron, methadoneCommon supportive drugs with QT risk
Action

Fridericia QTc above 500 ms or a rise of more than 60 ms from baseline: stop the responsible drug, keep potassium and magnesium in the high-normal range and stop other QT-prolonging drugs [3]. Resume according to the drug label once QTc has improved.

References

3 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Which QT Correction Formulae to Use for QT Monitoring?Vandenberk B, Vandael E, Robyns T, et al · J Am Heart Assoc · 2016;5
  2. 2
    Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic ReviewPorta-Sánchez A, Gilbert C, Spears D, et al · J Am Heart Assoc · 2017;6
  3. 3
    2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Lyon AR, López-Fernández T, Couch LS, et al · Eur Heart J · 2022;43:4229-4361
    Study cardDOIPubMed Back to text: 1 2

This page is based on reputable scientific sources and was last updated on 27 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.